# A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

> **NCT03635892** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
- Unclassified Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Succinate Dehydrogenase Deficient Renal Cell Carcinoma
- Collecting Duct Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma

## Interventions

- **DRUG:** cabozantinib
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT03635892
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-13
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635892, "A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03635892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*